Skip to content

Quanterix Corporation QTRX Cash & Equivalents

Cash & Equivalents at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$140.4M+10.4%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$25.57M+45.3%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%

Other financials

Income statement

See full
Revenue$36.4M+20.1%
Gross profit$15.6M+4.9%
Operating income-$41.4M-56.9%
Net income-$17.5M+14.5%
EPS (diluted)-$0.37+30.2%

Balance sheet

See full
Total debt$35.3M-2.9%
Total equity$282.1M-10.8%
Total assets$366.7M-7.5%

Cash flow

See full
Operating cash flow-$18.1M-30.4%
CapEx$87.0K-93.1%
Free cash flow-$18.2M-20.1%

Valuation

See full
Market cap$203.97M-20.1%
Enterprise value$203.12M+28.6%
P/S1.4×-0.6×

Profitability

See full
Gross margin44.2%-14.3pp
Operating margin-96.9%-1,691pp
Net margin-71.9%-2,019pp
FCF margin-57.2%-220pp

Returns & leverage

See full
Return on equity-34.8%-122pp
Debt / equity0.1×0.0×
Current ratio3.7×-4.6×

Where this comes from

Reported directly by Quanterix Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Quanterix Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quanterix Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quanterix Corporation's cash & equivalents?
Quanterix Corporation (QTRX) reported cash & equivalents of $36.18M in Q1 2026.
How has Quanterix Corporation's cash & equivalents changed year-over-year?
Quanterix Corporation's cash & equivalents decreased by 52.7% year-over-year, from $76.51M to $36.18M.
What is the long-term trend for Quanterix Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Quanterix Corporation's cash & equivalents has grown at a -30.3% compound annual growth rate (CAGR), from $181.58M to $29.84M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.